Theorem Clinical Research

Drug Sponsors

Sun Pharma closes merger deal with Ranbaxy

Thursday, March 26, 2015 02:52 PM

Sun Pharmaceutical Industries has begun the integration of Ranbaxy's business following the successful closure of its merger. The integration, planned by Sun Pharma since the announced merger in April 2014, will focus on supporting strong growth. According to Sun Pharma, the merger has fortified its position as the world's fifth largest specialty generic pharmaceutical company and the top ranking Indian pharma company.

More... »

Quest Diagnostics

Forma Therapeutics, Cancer Research Technology form two virtual companies

Wednesday, March 25, 2015 03:11 PM

Forma Therapeutics, headquartered in Watertown, Mass., and Cancer Research Technology (CRT) have formed two new virtual Asset Discovery and Development Companies (ADDCos) with novel chemical matter targeting undisclosed deubiquitinating enzymes (DUBs). ADDCos are virtual companies seeking to achieve rapid innovation in a compelling scientific area through the collaboration of academic thought leaders, drug discovery scientists and a development network.

More... »

Neovacs forms U.S. subsidiary

Wednesday, March 25, 2015 02:55 PM

Neovacs, a Paris-based biotechnology company focused on autoimmune and inflammatory diseases, has established a wholly-owned U.S. subsidiary, Neovacs Inc. Neovacs Inc. is headquartered in Boston and has been incorporated in Delaware.

More... »

Sanofi, Evotec collaborate to reinforce biomedical research in Toulouse

Wednesday, March 25, 2015 02:47 PM

Sanofi has signed a strategic collaboration agreement with Evotec, a drug discovery alliance and development partnership company, for scientific activities at the Sanofi R&D site in Toulouse (Haute-Garonne), France. This strategic collaboration aims to sustain a high level of scientific and technological activities, maintain jobs and attract new talent and projects to the site.

More... »

Biogen Idec becomes Biogen

Monday, March 23, 2015 03:41 PM

Biogen Idec has dropped the Idec from its name, in a new corporate identity and logo it says reflect both its evolution and focus on bringing forth new therapies in areas of high unmet need, while honoring Biogen’s scientific heritage and legacy as a pioneer in the biotechnology industry.

More... »

EUSA Pharma launches as independent pharma business

Monday, March 23, 2015 03:39 PM

EUSA Pharma (EUSA), a newly-established specialty pharmaceutical business with global reach, has officially launched, following the acquisition of five approved specialty hospital products, a multi-national commercial infrastructure and the EUSA Pharma brand name from Jazz Pharmaceuticals.

More... »

Janssen acquires XO1

Friday, March 20, 2015 02:13 PM

Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has acquired XO1, a U.K.-based privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab. Financial terms of the transaction have not been disclosed.

More... »

Coronado Biosciences, City of Hope form Mustang Therapeutics

Friday, March 20, 2015 02:03 PM

Coronado Biosciences has formed a new company, Mustang Therapeutics, in partnership with California research and treatment center City of Hope. Mustang initially will focus on the preclinical and clinical development, as well as commercialization of proprietary Chimeric Antigen Receptor (CAR-T) technology. The deal is valued in excess of $40 million for the development of these CAR-T cells via up-front and milestone payments to City of Hope. It is anticipated the first two CAR-T cells from this partnership will begin enrollment in human clinical trials at the City of Hope this year.

More... »

Certara opens larger corporate headquarters in New Jersey

Thursday, March 19, 2015 12:10 PM

Certara, a global biosimulation technology-enabled drug development and drug safety consulting company, is moving its corporate headquarters to a larger location in Princeton, N.J.

More... »

Valeant Pharmaceuticals counterbids Endo, offers Salix $1.45B

Wednesday, March 18, 2015 01:25 PM

Valeant Pharmaceuticals International and Salix Pharmaceuticals have entered into an amendment to their Agreement and Plan of Merger, dated Feb. 20. Valeant increased the offer price to acquire all the outstanding common stock of Salix from $158 per share to $199 per share, for aggregate gross proceeds of approximately $1.45 billion.

More... »


March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs